Results 21 to 30 of about 12,399 (131)

Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: A nationwide study in Hungary. [PDF]

open access: yes, 2014
We conducted a nationwide, full-population based investigation to evaluate the comparative effectiveness of all marketed second generation antipsychotic drugs (SGA) prescribed for outpatients with the diagnosis of schizophrenia in Hungary.
Bitter   +24 more
core   +1 more source

Psychiatric manifestations of multiple sclerosis and acute disseminated encephalomyelitis [PDF]

open access: yes, 2006
It is unusual for acute disseminated encephalomyelitis and multiple sclerosis to present as purely psychiatric disorders. We report five patients with such demyelinating diseases and symptoms of psychosis, depression or anxiety.
Brinar, Marko   +3 more
core   +1 more source

Response to antipsychotic drugs in treatment-resistant schizophrenia : Conclusions based on systematic review [PDF]

open access: yes, 2016
Peer ...
Corripio, I.   +10 more
core   +2 more sources

Antipsychotic‐Induced Hyperprolactinemia [PDF]

open access: yes, 2009
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90238/1/phco.29.1.64 ...
Bostwick, Jolene R.   +2 more
core   +1 more source

Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders [PDF]

open access: yes, 2019
Objective To systematically evaluate the efficacy of treatments for tics and the risks associated with their use. Methods This project followed the methodologies outlined in the 2011 edition of the American Academy of Neurology\u27s guideline development
Cavanna, Andrea E   +12 more
core   +2 more sources

Annual Research Review: Psychosis in children and adolescents: key updates from the past 2 decades on psychotic disorders, psychotic experiences, and psychosis risk

open access: yesJournal of Child Psychology and Psychiatry, Volume 66, Issue 4, Page 460-476, April 2025.
Psychosis in children and adolescents has been studied on a spectrum from (common) psychotic experiences to (rare) early‐onset schizophrenia spectrum disorders. This research review looks at the state‐of‐the‐art for research across the psychosis spectrum, from evidence on psychotic experiences in community and clinical samples of children and ...
Ian Kelleher
wiley   +1 more source

Pancreatitis following Olanzapine Therapy: A Report of Three Cases [PDF]

open access: yes, 2007
CONTEXT: Atypical antipsychotic agents (clozapine, olanzapine) have been linked to metabolic effects and acute pancreatitis. CASE REPORT: We reviewed the inpatient and outpatient records of three patients who developed acute pancreatitis while being ...
Azar, Riad   +3 more
core   +4 more sources

Metabolic Syndrome Screening in Seriously Mentally Ill Patients: A Quality Improvement Project [PDF]

open access: yes, 2016
A Project Submitted in Partial Fulfillment of the Requirements for the Degree of MASTER OF SCIENCE in Nursing ScienceSeriously mentally ill patients who are taking second-generation antipsychotics have a high risk of metabolic complications ...
Moreno, Annabel
core  

The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures. [PDF]

open access: yes, 2020
In comparison to batteries of standard neuropsychological tests, cognitive neuroscience tests may offer a more specific assessment of discrete neurobiological processes that may be aberrant in schizophrenia.
Ball, M Patricia   +21 more
core  

Establishing gold standard approaches to rapid tranquillisation: a review and discussion of the evidence on the safety and efficacy of medications currently used [PDF]

open access: yes, 2008
Background: Rapid tranquillisation is used when control of agitation, aggression or excitement is required. Throughout the UK there is no consensus over the choice of drugs to be used as first line treatment.
Branford, David   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy